- Patient outcomes with large core stroke damage are worse the larger the core volume and the longer the time lapse between stroke onset and treatment.
- Perfusion imaging may help identify large core stroke patients who are potential candidates for mechanical thrombectomy (clot removal).
Embargoed until 11 a.m. Hawaii Time/4 p.m. Eastern Time, Thursday, Feb. 7, 2019
HONOLULU, Feb. 7, 2019 —Mechanical clot removal has been shown to be safe and effective in stroke patients with minimal damaged brain tissue. Ideal patient selection may also someday hold promise for strokes damaging large areas of brain tissue, according to late breaking science presented at the American Stroke Association’s International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
“Outcomes in stroke patients treated with thrombectomy (mechanical clot removal) is affected by the size of the stroke – the larger the stroke, the worse the outcome,” said lead author Amrou Sarraj, M.D., associate professor of neurology at McGovern Medical School at The University of Texas Health Science Center at Houston.
In addition, longer time lapses between onset and treatment lowered good outcomes, with researchers noting much lower likelihood of benefit beyond 12 hours of stroke onset.
Currently, patients who a have large core stroke – large area of tissue damage – are routinely excluded from thrombectomy treatment. In this study, researchers evaluated such patients’ outcomes after mechanical clot removal.
Of 2,453 patients treated with mechanical clot removal, 221 had large core strokes. Thirty-five percent of those with large core strokes achieved functional independence three months after stroke, which was considered a good outcome.
However, the rate of good outcomes decreased and complications such as brain bleeds and death increased as the size of the stroke increased and the time to treatment increased.
Sarraj noted that while the safety outcomes (brain bleed up to 4 percent and deaths up to 12 percent) were reasonable in patients with strokes less than 100 mL volume, those complications were significantly higher in strokes that exceeded 100 mL in volume, with brain bleed in up to 75 percent of patients and deaths in up to 50 percent of patients.
Sarraj said advanced imaging to determine stroke size could extend thrombectomy treatment to more patients. Most upcoming stroke studies of this population use simple CT imaging of the brain to determine patient eligibility. This study evaluated patients with CT imaging and advanced imaging with contrast (perfusion imaging).
“The addition of perfusion imaging may help identify the best candidates who can benefit the most by thrombectomy procedure, which we implemented in the design of upcoming SELECT 2 trial,” Sarraj said.
Evidence from future randomized trials will help confirm these results to expand treatment eligibility and potentially help improve outcomes in many stroke patients, Sarraj added.
Co-authors and author disclosures are listed on the abstract. Stryker Neurovascular partially funded the study.
Note: Scientific presentation is 11:43 a.m. Hawaii Time/4:43 p.m. Eastern Time, Thursday, Feb. 7, 2019.
- VIDEO: Miguel Perez-Pinzon, Ph.D., FAHA, Chair, International Stroke Conference 2019 Program Committee, offers overviews and perspective on late breaking science via downloadable Skype video (transcript provided) available on the right column of the release link https://newsroom.heart.org/news/size-and-time-impact-outcomes-when-mechanical-clot-removal-used-for-large-core-strokes?preview=e6be81e40ff56e83e80a717bd6471583
- For more news from AHA International Stroke Conference 2019, follow us on Twitter @HeartNews #ISC19.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at https://www.heart.org/en/about-us/aha-financial-information.
About the American Stroke Association
The American Stroke Association is devoted to saving people from stroke — the No. 2 cause of death in the world and a leading cause of serious disability. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat stroke. The Dallas-based association officially launched in 1998 as a division of the American Heart Association. To learn more or to get involved, call 1-888-4STROKE or visit StrokeAssociation.org. Follow us on Facebook and Twitter.
For Media Inquiries and ASA Expert Perspective: 214-706-1173
Bridgette McNeill: 214-706-1135; firstname.lastname@example.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
Feb. 6-8, 2019: AHA News Media Office at the Honolulu Convention Center: 808-792-6530